Drug Trial Radar · NCT05210868
A Phase I/II Study of CM355 in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL)
Last checked: Nov 19, 2026Latest source record: Jan 27, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
184
Planned (sponsor's estimate)
Start
Nov 16, 2021
Primary completion
Dec 28, 2026
Study completion Dec 31, 2026
Sponsor
- Lead sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jan 27, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Phase I/II Open-Label, Single-Arm, Multicenter Clinical Study of CM355 in Patients With R/R B-NHL
Conditions
- Hematoma
Interventions
CM355Drug
1. Dose Escalation Phase CM355 will be taken by patients and will be treated follow the "3+3" dose escalation scheme 2. Expansion Phase CM355 will be taken by patients and will assess the efficacy of CM355 in patients with specific histopathological Non-Hodgkin's Lymphoma, and the safety of drug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose-limiting toxicities (DLT)Time frame: Up to 2 year
- Recommended phase II dose (RP2D) and/or (maximum tolerated dose) MTDTime frame: Up to 2 year
- Objective response rate(ORR)Time frame: through study completion,an average of 5 year
- The safety and tolerability of CM355Time frame: through study completion,an average of 5 year
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Beijing university cancer hospital
Beijing, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.